Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

The Fight Against the Medicare Part B Demonstration Project

Richard Quinn  |  October 28, 2016

The ACR and 315 other organizations have publicly said savings would not be achieved by the demonstration project and that it will reduce access to care for patients…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AdvocacyCenters for Medicare & Medicaid Services (CMS)CongressMedicareMedicare Part BMedicare ReimbursementReimbursement

Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD

Reuters Staff  |  October 4, 2016

NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPediatric Conditions Tagged with:adalimumabanti-TNF agentCrohn's diseaseinflammatory bowel diseaseinfliximabPediatriculcerative colitis

Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016

Thomas R. Collins  |  September 8, 2016

LONDON—The availability of a bio­similar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:benefitsBiosimilarsdrug updateEULAREuropean League Against Rheumatismpatient carepitfallResearchrheumatology

The Patient's Choice

When Rheumatologists Are a Patient’s Second or Third Choice for Medical Opinion

Charles Radis, DO  |  September 7, 2016

Outside Exam Room No. 5, the chart rack was empty, so I assumed my new consult was late. Just in case, I looked back over my shoulder as I passed by the partially open door and glimpsed the lower half of a woman holding a three-ringed binder on her lap. I squinted and took a…

Filed under:ConditionsPractice SupportPsoriatic Arthritis Tagged with:ArthritisLyme Diseasepatient carePractice ManagementPsoriatic ArthritisRheumatic Diseaserheumatologist

Adalimumab Lowers Risk of Uveitic Flare

Will Boggs, MD  |  August 30, 2016

NEW YORK (Reuters Health)—Adalimumab reduces the risk of uveitic flare after corticosteroid withdrawal in patients with inactive, noninfectious uveitis, according to results from VISUAL II. “Tumor-necrosis factor (TNF) inhibition, which has been demonstrated to have strong efficacy in rheumatologic disorders, can also have significant role in the management of noninfectious uveitis, even amidst the challenges…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabeyeInflammatory Eye DiseaseUveitis

Generic TNF-Alpha Inhibitors Comparable to Established Brands

David Douglas  |  August 3, 2016

NEW YORK (Reuters Health)—Biosimilar tumor necrosis factor-alpha inhibitors appear equivalent to the branded original versions, according to a systematic review and meta-analysis. As Dr. G. Caleb Alexander tells Reuters Health by email, “biologic treatments represent a rapidly growing proportion of prescription drug expenditures and thus there is enormous interest in whether or not biosimilar products…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsclinical trialsRheumatoid Arthritis (RA)TNF-Alpha inhibitor

U.S. FDA Panel Backs Valeant Psoriasis Drug with Risk Program

Toni Clarke  |  July 21, 2016

(Reuters)—Valeant Pharmaceuticals International Inc.’s experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory committees but typically…

Filed under:Biologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug AdministrationPsoriasisSafety

Biosimilars: Unanswered Questions

Susan Bernstein  |  July 5, 2016

Debate continues about how biosimilars that are emerging to treat rheumatic diseases will be named and monitored, said panelists at a recent meeting in Washington, D.C.—Biosimilars in the United States: Next Steps. Angus Worthing, MD, FACR, FACP, a member of the ACR’s Government Affairs Committee, shared rheumatologists’ concerns as these new therapies come to market….

Filed under:Biologics/DMARDsDrug Updates Tagged with:ACR Government Affairs CommitteeBiologics & Biosimilarsrheumatic diseases

The Gut Microbiome Influences Postmenopausal Bone Loss

Lara C. Pullen, PhD  |  June 27, 2016

Bone health has been successfully improved by using probiotics to influence the gut microbiome in postmenopausal women with osteoporosis. New research has gained insight into this process, uncovering that sex steroid depletion increases gut permeability resulting in inflammation and pathology in mice. Treatment with probiotics also prevents this increase in gut permeability and bone loss associated with sex steroid depletion…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonebone lossgut microbiomeMicrobiomeOsteoporosispostmenopauseWomen

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Rheumatoid Arthritis & Autoimmune Glomerulonephritis

Diana M. Girnita, MD, PhD, Shahzad Safdar, MD, & Avis Ware, MD  |  June 13, 2016

Rheumatoid arthritis (RA) is rarely associated with renal manifestations, but secondary amyloidosis due to chronic inflammation is reported to be the etiology of renal dysfunction in many cases of RA.1,2 The discovery of biologic therapy, with TNF-alpha inhibitors in particular, made a huge difference in the disease course and prognosis of RA patients. However, TNF-alpha…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Autoimmunecase reportClinicalDiagnosisGlomerulonephritisimmune complexpatient careRenalRheumatoid arthritisrheumatologyTNF-Alpha inhibitor

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences